Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 World Cancer Day 2023: where does the UK stand? February 3, 2023 Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... August 18, 2020 Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence... June 4, 2021 Load more HOT NEWS That Cancer Conversation is back! Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration
